The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-07-01
|
Series: | Journal of Virus Eradication |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020310670 |
id |
doaj-e5e7c642c977418ab426a4f6ff5ef76e |
---|---|
record_format |
Article |
spelling |
doaj-e5e7c642c977418ab426a4f6ff5ef76e2021-05-05T04:07:24ZengElsevierJournal of Virus Eradication2055-66402019-07-01523The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 InfectionC. Gay0J.D. Kuruc1S.D. Falcinelli2J. Warren3J.L. Kirchherr4K. Sholtis5B. Allard6E. Stuelke7A. Gamble8A. Plachco9I. Tcherapanova10J.J. Eron11N. Goonetilleke12M. DeBenedette13C.A. Nicolette14N.M. Archin15D.M. Margolis16UNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USADepartment of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAhttp://www.sciencedirect.com/science/article/pii/S2055664020310670 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
C. Gay J.D. Kuruc S.D. Falcinelli J. Warren J.L. Kirchherr K. Sholtis B. Allard E. Stuelke A. Gamble A. Plachco I. Tcherapanova J.J. Eron N. Goonetilleke M. DeBenedette C.A. Nicolette N.M. Archin D.M. Margolis |
spellingShingle |
C. Gay J.D. Kuruc S.D. Falcinelli J. Warren J.L. Kirchherr K. Sholtis B. Allard E. Stuelke A. Gamble A. Plachco I. Tcherapanova J.J. Eron N. Goonetilleke M. DeBenedette C.A. Nicolette N.M. Archin D.M. Margolis The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection Journal of Virus Eradication |
author_facet |
C. Gay J.D. Kuruc S.D. Falcinelli J. Warren J.L. Kirchherr K. Sholtis B. Allard E. Stuelke A. Gamble A. Plachco I. Tcherapanova J.J. Eron N. Goonetilleke M. DeBenedette C.A. Nicolette N.M. Archin D.M. Margolis |
author_sort |
C. Gay |
title |
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection |
title_short |
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection |
title_full |
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection |
title_fullStr |
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection |
title_full_unstemmed |
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection |
title_sort |
impact of vorinostat and ags-004, a dendritic cell-based immunotherapy, on persistent hiv-1 infection |
publisher |
Elsevier |
series |
Journal of Virus Eradication |
issn |
2055-6640 |
publishDate |
2019-07-01 |
url |
http://www.sciencedirect.com/science/article/pii/S2055664020310670 |
work_keys_str_mv |
AT cgay theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jdkuruc theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT sdfalcinelli theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jwarren theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jlkirchherr theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ksholtis theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ballard theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT estuelke theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT agamble theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT aplachco theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT itcherapanova theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jjeron theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ngoonetilleke theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT mdebenedette theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT canicolette theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT nmarchin theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT dmmargolis theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT cgay impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jdkuruc impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT sdfalcinelli impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jwarren impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jlkirchherr impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ksholtis impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ballard impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT estuelke impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT agamble impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT aplachco impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT itcherapanova impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT jjeron impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT ngoonetilleke impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT mdebenedette impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT canicolette impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT nmarchin impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection AT dmmargolis impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection |
_version_ |
1721475649812561920 |